An invariant surface patch on the TRIM5α PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding

Journal of Virology

Volumn 83, Issue 7, 2009, Pages 3365-3373

  Sebastian, Sarah ^a   Grütter, Christian ^b   De Castillia, Caterina Strambio ^c   Pertel, Thomas ^c,d   Olivari, Silvia ^c   Grütter, Markus G ^b   Luban, Jeremy ^a,c,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; TRIPARTITE MOTIF PROTEIN 5; CARRIER PROTEIN; TRIM5 PROTEIN, HUMAN;

ARTICLE; CRYSTAL STRUCTURE; CYTOPLASM; EQUINE INFECTIOUS ANEMIA VIRUS; FAMILIAL MEDITERRANEAN FEVER; GENE CLUSTER; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MURINE LEUKEMIA VIRUS; MUTAGENESIS; MUTANT; OPITZ SYNDROME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; VIRUS CAPSID; VIRUS INHIBITION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BINDING SITE; CELL LINE; CHEMICAL STRUCTURE; GENETICS; IMMUNOLOGY; METABOLISM; MISSENSE MUTATION; MOLECULAR GENETICS; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS;

EQUINE INFECTIOUS ANEMIA VIRUS; MIRIDAE; MURINE LEUKEMIA VIRUS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BINDING SITES; CAPSID PROTEINS; CARRIER PROTEINS; CELL LINE; HUMANS; INFECTIOUS ANEMIA VIRUS, EQUINE; LEUKEMIA VIRUS, MURINE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY;

EID: 63149175864     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00432-08     Document Type: Article

References (53)

1. Alber, T. 1989. Mutational effects on protein stability. Annu. Rev. Biochem. 58:765-798.
2. Altschul, S. F., T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389-3402.
3. Bass, S. H., M. G. Mulkerrin, and J. A. Wells. 1991. A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. Proc. Natl. Acad. Sci. USA 88:4498-4502.
4. Bennett, W. F., N. F. Paoni, B. A. Keyt, D. Botstein, A. J. Jones, L. Presta, F. M. Wurm, and M. J. Zoller. 1991. High resolution analysis of functional determinants on human tissue-type plasminogen activator. J. Biol. Chem. 266:5191-5201.
5. Berger, B., D. B. Wilson, E. Wolf, T. Tonchev, M. Milla, and P. S. Kim. 1995. Predicting coiled coils by use of pairwise residue correlations. Proc. Natl. Acad. Sci. USA 92:8259-8263.
6. Berthoux, L., S. Sebastian, D. M. Sayah, and J. Luban. 2005. Disruption of human TRIM5α antiviral activity by nonhuman primate orthologues. J. Virol. 79:7883-7888.
7. Bock, M., K. N. Bishop, G. Towers, and J. P. Stoye. 2000. Use of a transient assay for studying the genetic determinants of Fv1 restriction. J. Virol. 74:7422-7430.
8. Bowerman, B., P. O. Brown, J. M. Bishop, and H. E. Varmus. 1989. A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev. 3:469-478.
9. Combet, C., C. Blanchet, C. Geourjon, and G. Deleage. 2000. NPS@: network protein sequence analysis. Trends Biochem. Sci. 25:147-150.
10. Cowan, S., T. Hatziioannou, T. Cunningham, M. A. Muesing, H. G. Got-tlinger, and P. D. Bieniasz. 2002. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. USA 99:11914-11919.
11. Cunningham, B. C., and J. A. Wells. 1989. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244: 1081-1085.
12. Dao-Pin, S., D. E. Anderson, W. A. Baase, F. W. Dahlquist, and B. W. Matthews. 1991. Structural and thermodynamic consequences of burying a charged residue within the hydrophobic core of T4 lysozyme. Biochemistry 30:11521-11529.
13. Fassati, A., and S. P. Goff. 1999. Characterization of intracellular reverse transcription complexes of Moloney murine leukemia virus. J. Virol. 73: 8919-8925.
14. Grutter, C., C. Briand, G. Capitani, P. R. Mittl, S. Papin, J. Tschopp, and M. G. Grutter. 2006. Structure of the PRYSPRY-domain: implications for autoinflammatory diseases. FEBS Lett. 580:99-106.
15. Hatziioannou, T., D. Perez-Caballero, A. Yang, S. Cowan, and P. D. Bieniasz. 2004. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5α. Proc. Natl. Acad. Sci. USA 101:10774-10779.
16. James, L. C., A. H. Keeble, Z. Khan, D. A. Rhodes, and J. Trowsdale. 2007. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc. Natl. Acad. Sci. USA 104:6200-6205.
17. Javanbakht, H., W. Yuan, D. F. Yeung, B. Song, F. Diaz-Griffero, Y. Li, X. Li, M. Stremlau, and J. Sodroski. 2006. Characterization of TRIM5α trimer-ization and its contribution to human immunodeficiency virus capsid binding. Virology 353:234-246.
18. Keckesova, Z., L. M. Ylinen, and G. J. Towers. 2004. The human and African green monkey TRIM5α genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. USA 101:10780- 10785.
19. Kleywegt, G. J., and T. A. Jones. 1998. Databases in protein crystallography. Acta Crystallogr. D 54:1119-1131.
20. Laskowski, R. A., J. A. Rullmannn, M. W. MacArthur, R. Kaptein, and J. M. Thornton. 1996. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8:477-486.
21. Li, Y., X. Li, M. Stremlau, M. Lee, and J. Sodroski. 2006. Removal of arginine 332 allows human TRIM5α to bind human immunodeficiency virus capsids and to restrict infection. J. Virol. 80:6738-6744.
22. Mische, C. C., H. Javanbakht, B. Song, F. Diaz-Griffero, M. Stremlau, B. Strack, Z. Si, and J. Sodroski. 2005. Retroviral restriction factor TRIM5α is a trimer. J. Virol. 79:14446-14450.
23. Mitrophanous, K., S. Yoon, J. Rohll, D. Patil, F. Wilkes, V. Kim, S. Kings-man, A. Kingsman, and N. Mazarakis. 1999. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6:1808-1818.
24. Nakayama, E. E., H. Miyoshi, Y. Nagai, and T. Shioda. 2005. A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5α determines species-specific restriction of simian immunodeficiency virus SIVmac infection. J. Virol. 79:8870-8877.
25. Naviaux, R. K., E. Costanzi, M. Haas, and I. M. Verma. 1996. The pCL vector system: rapid production of helper-free, high-titer, recombinant ret-rovirases. J. Virol. 70:5701-5705.
26. Ohkura, S, M. W. Yap, T. Sheldon, and J. P. Stoye. 2006. All three variable regions of the TRIM5α B30.2 domain can contribute to the specificity of retroviras restriction. J. Virol. 80:8554-8565.
27. Perez-Caballero, D., T. Hatziioannou, A. Yang, S. Cowan, and P. D. Bien-iasz. 2005. Human tripartite motif 5α domains responsible for retroviras restriction activity and specificity. J. Virol. 79:8969-8978.
28. Perez-Caballero, D., T. Hatziioannou, F. Zhang, S. Cowan, and P. D. Bien-iasz. 2005. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J. Virol. 79:15567-15572.
29. Perron, M. J., M. Stremlau, M. Lee, H. Javanbakht, B. Song, and J. Sodroski. 2007. The human TRIM5α restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J. Virol. 81:2138-2148.
30. Perron, M. J., M. Stremlau, and J. Sodroski. 2006. Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5α. J. Virol. 80:5631-5636.
31. Perron, M. J., M. Stremlau, B. Song, W. Ulm, R. C. Mulligan, and J. Sodroski. 2004. TRIM5α mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. USA 101:11827-11832.
32. Reymond, A., G. Meroni, A. Fantozzi, G. Merla. S. Cairo, L. Luzi, D. Riganelli, E. Zanaria. S. Messali, S. Cainarca. A. Guffanti, S. Minucci, P. G. Pelicci, and A. Ballabio. 2001. The tripartite motif family identifies cell compartments. EMBO J. 20:2140-2151.
33. Sebastian, S., and J. Luban. 2005. TRIM5α selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2:40.
34. Sebastian, S., E. Sokolskaja, and J. Luban. 2006. Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner. J. Virol. 80:2051-2054.
35. Sokolskaja, E., L. Berthoux, and J. Luban. 2006. Cyclophilin A and TRIM5ct independently regulate human immunodeficiency virus type 1 infectivity in human cells. J. Virol. 80:2855-2862.
36. Song, B., F. Diaz-Griffero, H. Park Do, T. Rogers, M. Stremlau, and J. Sodroski. 2005. TRIM5α association with cytoplasmic bodies is not required for antiretroviral activity. Virology 343:201-211.
37. Song, B., B. Gold, C. O'Huigin, H. Javanbakht, X. Li, M. Stremlau, C. Winkler, M. Dean, and J. Sodroski. 2005. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5α exhibits lineage-specific length and sequence variation in primates. J. Virol. 79:6111-6121.
38. Song, B., H. Javanbakht, M. Perron, D. H. Park, M. Stremlau, and J. Sodroski. 2005. Retroviras restriction by TRIM5α variants from Old World and New World primates. J. Virol. 79:3930-3937.
39. Stremlau, M., C. M. Owens, M. J. Perron, M. Kiessling, P. Autissier, and J. Sodroski. 2004. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.
40. Stremlau, M., M. Perron, M. Lee, Y. Li, B. Song, H. Javanbakht, F. Diaz-Griffero, D. J. Anderson, W. I. Sundquist, and J. Sodroski. 2006. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5α restriction factor. Proc. Natl. Acad. Sci. USA 103:5514- 5519.
41. Stremlau, M., M. Perron, S. Welikala, and J. Sodroski. 2005. Species-specific variation in the B30.2(SPRY) domain of TRIM5α determines the potency of human immunodeficiency virus restriction. J. Virol. 79:3139-3145.
42. Thompson, J. D., T. J. Gibson, F. Plewniak, F. Jeanmougin, and D. G. Higgins. 1997. The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25:4876-4882.
43. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
44. Towers, G., M. Collins, and Y. Takeuchi. 2002. Abrogation of Refl retroviras restriction in human cells. J. Virol. 76:2548-2550.
45. Towers, G. J., T. Hatziioannou, S. Cowan, S. P. Goff, J. Luban, and P. D. Bieniasz. 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9:1138-1143.
46. Van Parijs, L., Y. Refaeli, J. D. Lord, B. H. Nelson, A. K. Abbas, and D. Baltimore. 1999. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 11:281-288.
47. Welker, R., H. Hohenberg, U. Tessmer, C. Huckhagel, and H. G. Krausslich. 2000. Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J. Virol. 74:1168-1177.
48. Wertman, K. F., D. G. Drubin, and D. Botstein. 1992. Systematic mutational analysis of the yeast ACT1 gene. Genetics 132:337-350.
49. Woo, J. S., J. H. Imm, C. K. Min, K. J. Kim, S. S. Cha, and B. H. Oh. 2006. Structural and functional insights into the B30.2/SPRY domain. EMBO J. 25:1353-1363.
50. Yap, M. W., S. Nisole, C. Lynch, and J. P. Stoye. 2004. Trim5α protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. USA 101:10786-10791.
51. Yap, M. W., S. Nisole, and J. P. Stoye. 2005. A single amino acid change in the SPRY domain of human Trim5α leads to HIV-1 restriction. Curr. Biol. 15:73-78.
52. Yee, J. K., A. Miyanohara, P. LaPorte, K. Bouic, J. C. Burns, and T. Friedmann. 1994. A general method for the generation of high-titer, pan-tropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA 91:9564-9568.
53. Zhang, F., T. Hatziioannou, D. Perez-Caballero, D. Derse, and P. D. Bieniasz. 2006. Antiretroviral potential of human tripartite motif-5 and related proteins. Virology 353:396-409.